Immunotherapy in non-small cell lung cancer: rationale, recent advances and future perspectives

Lung cancer, with non-small cell lung cancer (NSCLC) being the major type, is the second most common malignancy and the leading cause of cancer-related death globally. Immunotherapy, represented by immune checkpoint inhibitors (ICIs), has been one of the greatest advances in recent years for the tre...

Descripción completa

Detalles Bibliográficos
Autores principales: Luo, Wenxin, Wang, Zhoufeng, Zhang, Ting, Yang, Lan, Xian, Jinghong, Li, Yalun, Li, Weimin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8982543/
https://www.ncbi.nlm.nih.gov/pubmed/35692863
http://dx.doi.org/10.1093/pcmedi/pbab027

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8982543/
https://www.ncbi.nlm.nih.gov/pubmed/35692863
http://dx.doi.org/10.1093/pcmedi/pbab027

Ejemplares similares